{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:45Z","timestamp":1790878365967,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5415-9","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T09:08:22Z","timestamp":1551863302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Challenges of driving CD30-directed CAR-T cells to the clinic"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"issue":"2","key":"5415_CR1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5415_CR2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"5\u20136","key":"5415_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","volume":"18","author":"RH Scheuermann","year":"1995","unstructured":"Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18(5\u20136):385\u201397.","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"5415_CR4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"26","key":"5415_CR5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"12","key":"5415_CR6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ajh.24184","volume":"90","author":"I Glimelius","year":"2015","unstructured":"Glimelius I, Ekberg S, Jerkeman M, Chang ET, Bjorkholm M, Andersson TM, Smedby KE, Eloranta S. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. Am J Hematol. 2015;90(12):1128\u201334.","journal-title":"Am J Hematol"},{"issue":"9323","key":"5415_CR7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet (London, England). 2002;359(9323):2065\u201371.","journal-title":"Lancet (London, England)"},{"issue":"18","key":"5415_CR8","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","volume":"115","author":"B Sarina","year":"2010","unstructured":"Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, Falda M, Guidi S, Ciceri F, Bonini A, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671\u20137.","journal-title":"Blood"},{"issue":"1","key":"5415_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","volume":"126","author":"G Hapgood","year":"2015","unstructured":"Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17\u201325.","journal-title":"Blood"},{"issue":"3","key":"5415_CR10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","volume":"68","author":"H D\u00fcrkop","year":"1992","unstructured":"D\u00fcrkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68(3):421\u20137.","journal-title":"Cell"},{"issue":"4","key":"5415_CR11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.bloodjournal664848","volume":"66","author":"H Stein","year":"1985","unstructured":"Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848\u201358.","journal-title":"Blood"},{"issue":"1","key":"5415_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","volume":"10","author":"JM Pierce","year":"2017","unstructured":"Pierce JM, Mehta A. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Rev Hematol. 2017;10(1):29\u201337.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"5415_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","volume":"10","author":"R Horie","year":"1998","unstructured":"Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457\u201370.","journal-title":"Semin Immunol"},{"issue":"1","key":"5415_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","volume":"85","author":"B Falini","year":"1995","unstructured":"Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1\u201314.","journal-title":"Blood"},{"issue":"6","key":"5415_CR15","first-page":"1116","volume":"58","author":"A Hombach","year":"1998","unstructured":"Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58(6):1116\u20139.","journal-title":"Cancer Res"},{"issue":"18","key":"5415_CR16","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"5415_CR17","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5415_CR18","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562\u20136.","journal-title":"Blood"},{"issue":"23","key":"5415_CR19","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050\u20136.","journal-title":"Blood"},{"issue":"5","key":"5415_CR20","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549\u201355.","journal-title":"Blood"},{"issue":"5","key":"5415_CR21","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822\u20136.","journal-title":"J Clin Invest"},{"issue":"6","key":"5415_CR22","first-page":"473","volume":"22","author":"A Hombach","year":"1999","unstructured":"Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother (Hagerstown, Md : 1997). 1999;22(6):473\u201380.","journal-title":"J Immunother (Hagerstown, Md : 1997)"},{"issue":"7","key":"5415_CR23","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","volume":"110","author":"B Savoldo","year":"2007","unstructured":"Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620\u201330.","journal-title":"Blood"},{"issue":"1","key":"5415_CR24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107\u201326.","journal-title":"Immunol Rev"},{"issue":"1\u20132","key":"5415_CR25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.imlet.2013.09.014","volume":"155","author":"B Savoldo","year":"2013","unstructured":"Savoldo B, Dotti G. Chimeric antigen receptors (CARs) from bench-to-bedside. Immunol Lett. 2013;155(1\u20132):40\u20132.","journal-title":"Immunol Lett"},{"issue":"6","key":"5415_CR26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370\u201383.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"5415_CR27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","volume":"24","author":"AA Hombach","year":"2016","unstructured":"Hombach AA, Gorgens A, Chmielewski M, Murke F, Kimpel J, Giebel B, Abken H. Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol Ther. 2016;24(8):1423\u201334.","journal-title":"Mol Ther"},{"issue":"12","key":"5415_CR28","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1182\/blood-2006-11-055921","volume":"109","author":"J Beckmann","year":"2007","unstructured":"Beckmann J, Scheitza S, Wernet P, Fischer JC, Giebel B. Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins. Blood. 2007;109(12):5494\u2013501.","journal-title":"Blood"},{"issue":"2","key":"5415_CR29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/1744666X.2016.1221763","volume":"13","author":"AA Hombach","year":"2017","unstructured":"Hombach AA, Abken H. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells? Expert Rev Clin Immunol. 2017;13(2):151\u20135.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"5415_CR30","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/2326-6066.CIR-18-0065","volume":"6","author":"LK Hong","year":"2018","unstructured":"Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G, Savoldo B. CD30-redirected chimeric antigen receptor T cells target CD30(+) and CD30(\u2212) embryonal carcinoma via antigen-dependent and Fas\/FasL interactions. Cancer Immunol Res. 2018;6(10):1274\u201387.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"5415_CR31","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5415_CR32","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462\u201371.","journal-title":"J Clin Invest"},{"issue":"18","key":"5415_CR33","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"6","key":"5415_CR34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","volume":"14","author":"KJ Curran","year":"2012","unstructured":"Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012;14(6):405\u201315.","journal-title":"J Gene Med"},{"issue":"6","key":"5415_CR35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3109\/21691401.2015.1052465","volume":"44","author":"M Haji-Fatahaliha","year":"2016","unstructured":"Haji-Fatahaliha M, Hosseini M, Akbarian A, Sadreddini S, Jadidi-Niaragh F, Yousefi M. CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol. 2016;44(6):1339\u201349.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"4","key":"5415_CR36","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 2013;8(4):e61338.","journal-title":"PLoS One"},{"issue":"5","key":"5415_CR37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","volume":"103","author":"NA Marshall","year":"2004","unstructured":"Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103(5):1755\u201362.","journal-title":"Blood"},{"issue":"3","key":"5415_CR38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000094678","volume":"116","author":"S Barath","year":"2006","unstructured":"Barath S, Aleksza M, Keresztes K, Toth J, Sipka S, Szegedi G, Illes A. Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma. Acta Haematol. 2006;116(3):181\u20135.","journal-title":"Acta Haematol"},{"key":"5415_CR39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2013.07.002","volume":"24","author":"Y Liu","year":"2014","unstructured":"Liu Y, Sattarzadeh A, Diepstra A, Visser L, van den Berg A. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol. 2014;24:15\u201322.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"5415_CR40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/joim.12582","volume":"281","author":"I Glimelius","year":"2017","unstructured":"Glimelius I, Diepstra A. Novel treatment concepts in Hodgkin lymphoma. J Intern Med. 2017;281(3):247\u201360.","journal-title":"J Intern Med"},{"issue":"1","key":"5415_CR41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","volume":"263","author":"S Gill","year":"2015","unstructured":"Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015;263(1):68\u201389.","journal-title":"Immunol Rev"},{"issue":"6","key":"5415_CR42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5415_CR43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26(2):111\u20137.","journal-title":"Trends Immunol"},{"issue":"25","key":"5415_CR44","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Stasi Di","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392\u2013402.","journal-title":"Blood"},{"issue":"6","key":"5415_CR45","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","volume":"154","author":"A Berg van den","year":"1999","unstructured":"van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol. 1999;154(6):1685\u201391.","journal-title":"Am J Pathol"},{"issue":"11","key":"5415_CR46","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","volume":"66","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006;66(11):5716\u201322.","journal-title":"Cancer Res"},{"issue":"10","key":"5415_CR47","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875\u201385.","journal-title":"N Engl J Med"},{"issue":"23","key":"5415_CR48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood.V126.23.583.583","volume":"126","author":"S Ansell","year":"2015","unstructured":"Ansell S, Armand P, Timmerman JM, Shipp MA, Bradley Garelik MB, Zhu L, Lesokhin AM. Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Blood. 2015;126(23):583.","journal-title":"Blood"},{"key":"5415_CR49","doi-asserted-by":"crossref","unstructured":"Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J, Zhu Y, Ricart AD, Balakumaran A, Moskowitz CH. Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure: long-term efficacy from the phase 1b Keynote-013 study. In: Am Soc Hematology. 2016.","DOI":"10.1182\/blood.V128.22.1108.1108"},{"key":"5415_CR50","doi-asserted-by":"crossref","unstructured":"Maude SL, Hucks GE, Seif AE, Talekar MK, Teachey DT, Baniewicz D, Callahan C, Gonzalez V, Nazimuddin F, Gupta M, Frey NV, Porter DL, Levine BL, Melenhorst JJ, Lacey SF, June CH, Grupp SA. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology; 2017;35(15_suppl);103\u2013103.","DOI":"10.1200\/JCO.2017.35.15_suppl.103"},{"issue":"8","key":"5415_CR51","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341.","journal-title":"Blood"},{"issue":"1","key":"5415_CR52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg A-M, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"5415_CR53","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","volume":"21","author":"B Tresckow von","year":"2015","unstructured":"von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A. An open-label, multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Clin Cancer Res. 2015;21(8):1843\u201350.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5415-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5415-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5415-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T04:24:03Z","timestamp":1606623843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5415-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5415"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5415-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735264826.793577575","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"16 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"203"}}